{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:21:11Z","timestamp":1790716871126,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.pnpbp.2026.111893","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T06:24:49Z","timestamp":1787034289000},"page":"111893","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Genetic and epigenetic determinants of cytochrome P450 activity in psychopharmacology: from pharmacogenetics to functional pharmacogenomics"],"prefix":"10.1016","volume":"149","author":[{"given":"Marijose","family":"Laureano-Rivera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"de Jes\u00fas Reyes-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Minauro-Sanmiguel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9ctor","family":"Vargas-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Cecilia","family":"Cepeda-Nieto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pnpbp.2026.111893_bb0005","doi-asserted-by":"crossref","first-page":"11203","DOI":"10.3389\/fphar.2025.1611203","article-title":"Epigenetics in pharmacogenes encoding metabolizing enzymes of second-generation antipsychotics used in schizophrenia and its clinical implications","volume":"16","author":"Alvarado","year":"2025","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.pnpbp.2026.111893_bb0010","doi-asserted-by":"crossref","first-page":"78","DOI":"10.5603\/mrj.104291","article-title":"Potential association of CYPs, COMT, DRD2, 5HTR2A polymorphisms with susceptibility to the adverse effect of aripiprazole: preliminary observations","volume":"10","author":"Bartosiewicz","year":"2025","journal-title":"Med. Res. J."},{"issue":"3","key":"10.1016\/j.pnpbp.2026.111893_bb0015","first-page":"133","article-title":"Pharmacogenetic tests and depressive symptom remission: a meta-analysis of randomized controlled trials","volume":"24","author":"Bousman","year":"2023","journal-title":"Pharmacogenomics"},{"issue":"1","key":"10.1016\/j.pnpbp.2026.111893_bb0020","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/cts.12692","article-title":"Standardizing CYP2D6 genotype to phenotype translation: consensus recommendations from the clinical pharmacogenetics implementation consortium and Dutch pharmacogenetics working group","volume":"13","author":"Caudle","year":"2020","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.pnpbp.2026.111893_bb0025","doi-asserted-by":"crossref","unstructured":"Cavaleri D, Bassetti C, Cucchi G, et al. Metabolomics biomarkers for precision psychiatry. Front. Psychiatry 2026;17:1736206. Published 2026 Feb 13. doi:https:\/\/doi.org\/10.3389\/fpsyt.2026.1736206.","DOI":"10.3389\/fpsyt.2026.1736206"},{"issue":"5","key":"10.1016\/j.pnpbp.2026.111893_bb0030","first-page":"448","article-title":"Treatment resistance in schizophrenia: a meta-analysis of prevalence and correlates","volume":"45","author":"Diniz","year":"2023","journal-title":"Rev. Bras. Psiquiatr."},{"key":"10.1016\/j.pnpbp.2026.111893_bb0035","series-title":"CYP1A2 Gene","author":"GeneCards","year":"2026"},{"key":"10.1016\/j.pnpbp.2026.111893_bb0040","series-title":"CYP2B6 Gene","author":"GeneCards","year":"2026"},{"key":"10.1016\/j.pnpbp.2026.111893_bb0045","series-title":"CYP2C19 Gene","author":"GeneCards","year":"2026"},{"key":"10.1016\/j.pnpbp.2026.111893_bb0050","series-title":"CYP2D6 Gene","author":"GeneCards","year":"2026"},{"key":"10.1016\/j.pnpbp.2026.111893_bb0055","series-title":"CYP3A4 Gene","author":"GeneCards","year":"2026"},{"key":"10.1016\/j.pnpbp.2026.111893_bb0060","series-title":"CYP3A5 Gene","author":"GeneCards","year":"2026"},{"issue":"5","key":"10.1016\/j.pnpbp.2026.111893_bb0065","first-page":"1016","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and antidepressant dosing: 2023 update","volume":"113","author":"Hicks","year":"2023","journal-title":"Clin. Pharmacol. Ther. (St. Louis, MO, U. S.)"},{"issue":"1","key":"10.1016\/j.pnpbp.2026.111893_bb0070","first-page":"1","article-title":"Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2023","volume":"56","author":"Hiemke","year":"2023","journal-title":"Pharmacopsychiatry"},{"issue":"1","key":"10.1016\/j.pnpbp.2026.111893_bb0075","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s40246-018-0157-3","article-title":"Integrating rare genetic variants into pharmacogenetic drug response predictions","volume":"14","author":"Ingelman-Sundberg","year":"2020","journal-title":"Hum. Genomics"},{"issue":"5","key":"10.1016\/j.pnpbp.2026.111893_bb0080","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1176\/appi.ajp.2017.17050550","article-title":"Effect of CYP2C19 genotype on escitalopram exposure and therapeutic failure: a retrospective study based on 2,087 patients","volume":"178","author":"Jukic","year":"2021","journal-title":"Am. J. Psychiatry"},{"issue":"11","key":"10.1016\/j.pnpbp.2026.111893_bb0085","first-page":"2731","article-title":"Pharmacogenetics-guided dose adjustments of antidepressants and antipsychotics: a review of the current literature","volume":"25","author":"Kirchheiner","year":"2020","journal-title":"Mol. Psychiatry"},{"issue":"10","key":"10.1016\/j.pnpbp.2026.111893_bb0090","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1176\/appi.ajp.2017.16121358","article-title":"Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, Bayesian meta-analysis, and meta-regression of efficacy predictors","volume":"174","author":"Leucht","year":"2017","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111893_bb0095","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.schres.2021.05.010","article-title":"Toward personalized medicine in schizophrenia: genetics and epigenetics of antipsychotic treatment","volume":"232","author":"Lisoway","year":"2021","journal-title":"Schizophr. Res."},{"issue":"1","key":"10.1016\/j.pnpbp.2026.111893_bb0100","doi-asserted-by":"crossref","DOI":"10.1186\/s12888-020-03034-9","article-title":"Effect of CYP2D6 polymorphisms on plasma concentration and therapeutic effect of risperidone","volume":"21","author":"Lu","year":"2021","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111893_bb0105","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jad.2020.02.023","article-title":"The identification, assessment and management of difficult-to-treat depression: an international consensus statement","volume":"267","author":"McAllister-Williams","year":"2020","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.pnpbp.2026.111893_bb0110","author":"National Center for Biotechnology Information"},{"key":"10.1016\/j.pnpbp.2026.111893_bb0115","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.pnpbp.2017.10.004","article-title":"DNA methylation and antipsychotic treatment mechanisms in schizophrenia: Progress and future directions","volume":"81","author":"Ovenden","year":"2018","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"10197","key":"10.1016\/j.pnpbp.2026.111893_bb0120","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0140-6736(19)31276-0","article-title":"Pharmacogenomics","volume":"394","author":"Roden","year":"2021","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.pnpbp.2026.111893_bb0125","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s40291-020-00464-9","article-title":"Exploiting circulating MicroRNAs as biomarkers in psychiatric disorders","volume":"24","author":"Roy","year":"2020","journal-title":"Mol. Diagn. Ther."},{"issue":"11","key":"10.1016\/j.pnpbp.2026.111893_bb0130","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","article-title":"Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report","volume":"163","author":"Rush","year":"2006","journal-title":"Am. J. Psychiatry"},{"issue":"97","key":"10.1016\/j.pnpbp.2026.111893_bb0135","article-title":"Genetic testing for antipsychotic pharmacotherapy: bench to bedside","volume":"11","author":"Shad","year":"2021","journal-title":"Behav. Sci."},{"issue":"7","key":"10.1016\/j.pnpbp.2026.111893_bb0140","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2017.143","article-title":"Combined study of genetic and epigenetic biomarker risperidone treatment efficacy in Chinese Han schizophrenia patients","volume":"7","author":"Shi","year":"2017","journal-title":"Transl. Psychiatry"},{"issue":"7","key":"10.1016\/j.pnpbp.2026.111893_bb0145","first-page":"2776","article-title":"Genetic variability of drug-metabolizing enzymes: the dual impact on psychiatric therapy and regulation of brain function","volume":"26","author":"Stingl","year":"2021","journal-title":"Mol. Psychiatry"},{"issue":"D1","key":"10.1016\/j.pnpbp.2026.111893_bb0150","doi-asserted-by":"crossref","first-page":"D638","DOI":"10.1093\/nar\/gkac1000","article-title":"The STRING database in 2023: protein-protein association networks and functional enrichment analyses for any sequenced genome of interest","volume":"51","author":"Szklarczyk","year":"2023","journal-title":"Nucleic Acids Res."},{"issue":"41","key":"10.1016\/j.pnpbp.2026.111893_bb0155","article-title":"Risperidone plasma level, and its correlation with CYP2D6 gene polymorphism, clinical response and side effects in chronic schizophrenia patients","volume":"24","author":"Wang","year":"2024","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111893_bb0160","article-title":"Clinical pharmacogenetics of cytochrome P450 enzymes in drug metabolism and personalized medicine","volume":"232","author":"Zhou","year":"2022","journal-title":"Pharmacol. Ther."},{"issue":"7","key":"10.1016\/j.pnpbp.2026.111893_bb0165","first-page":"451","article-title":"Worldwide distribution of cytochrome P450 alleles and their clinical implications","volume":"23","author":"Zhou","year":"2022","journal-title":"Nat. Rev. Genet."}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584626002915?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584626002915?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:48:50Z","timestamp":1790714930000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278584626002915"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":33,"alternative-id":["S0278584626002915"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2026.111893","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genetic and epigenetic determinants of cytochrome P450 activity in psychopharmacology: from pharmacogenetics to functional pharmacogenomics","name":"articletitle","label":"Article Title"},{"value":"Progress in Neuro-Psychopharmacology and Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pnpbp.2026.111893","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"111893"}}